L 653328
Alternative Names: BPPALatest Information Update: 22 Jul 1998
At a glance
- Originator Merck & Co
- Class Antiglaucomas
- Mechanism of Action Beta adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 22 Jul 1998 No-Development-Reported for Glaucoma in USA (Ophthalmic)
- 30 Dec 1993 Phase-II clinical trials for Glaucoma in USA (Ophthalmic)